Greg Duncan 

Chief Executive Officer

Chairman of BoD 

Richard Burch


Ralph Grosswald  

Vice President
of Operations 

Angela Walsh 

Vice President of Finance, Treasurer 

R. Michael Gendreau, 
MD, PhD 

Chief Medical

Greg Duncan is the Chief Executive Officer and a Member of the Board of Directors of Virios Therapeutics. Previously, Mr. Duncan  was President and Chief Executive Officer of Celtaxsys, Inc., a privately held biotech company focused on developing anti-inflammatory medicines for rare disease where he scaled the required capital to build out the organizational capability to advance both pre- clinical and clinical development candidates.  Prior to Celtaxsys, he served as an Executive Committee member at Belgium based UCB, a specialty pharma entity developing and commercializing medicines for immunologic and central nervous system disorders. Before joining UCB, Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat. Mr. Duncan has served as director for Biotie Therapeutics, the American Psychiatric Foundation, Bio International Organization (BIO), Southeast BIO (SEBIO and the Georgia Bio industry association groups. Greg holds a master’s degree in business administration from Emory University in Atlanta, GA, and a bachelor’s degree in economics from the State University of New York in Albany, NY.

Richard Burch is the President of Virios Therapeutics.  Prior to joining Virios, Mr. Burch spent 30 years at Pfizer starting as a sales rep and working his way up to Senior Vice President overseeing numerous divisions with more than 6,500 employees. He was accountable for $11.5 billion in revenue and had responsibilities in launching or managing over
20 pharmaceutical products, including blockbuster brands such as Celebrex, Lyrica, Aricept, Zoloft, Rebif, Zithromax and Lipitor.  Following his tenure at Pfizer, Mr. Burch was named Vice President and General Manager for UCB, Inc., overseeing all operations for the US CNS Business Unit including P&L management and responsibility for pipeline and in-line portfolio of CNS products. Mr. Burch currently serves on the University of Alabama Business School Board and is a member of the University of Alabama President’s Cabinet and on the Executive Committee for the DCH Health System Foundation Board. Mr. Burch received a bachelor’s degree in Marketing from the University of Alabama and certification from the Finance and Accounting Department of Columbia University’s Graduate School of Business.

R. Michael Gendreau, M.D., Ph.D. is the Chief Medical Officer of Virios Therapeutics. Dr. Gendreau has been a healthcare consultant specializing in biotechnology for Gendreau Consulting, LLC. He received his B.S. in chemistry from Ohio University and his M.D./Ph.D. in medicine and pharmacology from The Ohio State University College of Medicine. Before starting his own consulting firm, Dr. Gendreau worked at Cypress Bioscience, Inc. holding various positions including Vice President of Research and Development and Chief Medical Officer. Before joining Cypress Bioscience, Inc., Dr. Gendreau was Vice President of Research and Development and Chief Medical Officer for MicroProbe Corporation, a developer and manufacturer of DNA/RNA probe- based diagnostic products.

Ralph Grosswald has 25 years of experience developing innovative drugs and medical devices. Previously, Mr.  Grosswald was a founder and Vice President of Operations at Celtaxsys, Inc. where he managed operations, nonclinical development  and clinical trials of acebilustat  for the treatment of cystic fibrosis. Prior to that, Mr. Grosswald started GMP Companies, Inc. where he managed development the programs of the first ever Microinvasive Glaucoma Shunt and the LifeSync Wireless ECG. Before joining GMP, he was the Director of Outcomes Research for the National Healthcare Network, a cardiovascular centers of excellence managed care network partnered with the Duke Clinical Research Institute. Mr. Grosswald began his career as a clinical trial coordinator for both interventional cardiology and cardiothoracic surgery studies at the Emory University School of Medicine from 1990 to 1997. Mr. Grosswald holds B.A. and Master of Public Health degrees from Emory University.

Angela Walsh is the Vice President of Finance and Treasurer of Virios Therapeutics. Ms. Walsh has over three decades of experience in the field of financial management and accounting, specializing in mergers and acquisitions, strategic planning, compliance and risk management, financial modeling, budgeting, and forecasting.  She was the VP of Finance for Celtaxsys, Inc. where she oversaw and managed the company’s financial and accounting activities. Prior
to that, Ms. Walsh worked at Vennskap,  LLC and was the CFO for Green Circle Bio Energy where she part of the executive team that executed a successful acquisition  by Enviva Partners, LP, which subsequently executed a $214M initial public offering. Prior to that, she worked at Atlanco and at Altea Therapeutics. Ms. Walsh was the Controller for Huffy Sports, a division of the Russell Corporation and participated in numerous capital market transactions including mergers and acquisitions, debt offerings and filing S-1s for initial public offerings. Ms. Walsh began her accounting career with Arthur Anderson and is a Certified Public Accountant in both Georgia and North Carolina. Ms. Walsh holds a BS in Accounting from Wake Forest University.